|
Alexion Pharmaceuticals can't suppress its enthusiasm for treating immune functions gone awry. The firm develops drugs that inhibit certain immune system functions that cause autoimmune disorders, cancers, and other diseases. The company's first marketed antibody product, Soliris, has won approval in the US, Canada, and the European Union for the treatment of a rare genetic blood disorder known as paroxysmal nocturnal hemoglobinuria (PNH). Alexion is developing the same antibody (eculizumab) used in Soliris as a potential treatment for other autoimmune and inflammatory conditions. The company has additional development programs for cancer-fighting antibodies.
|
| | | Contact Information | |
Address: |
352 Knotter Dr.
Cheshire, CT 06410
| | Phone: | 203-272-2596 | | Fax: | 203-271-8198 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 259.10 M | | Revenue Growth (1 yr): | 259.70% | | Employees (2008): | 504 | | Employee Growth (1 yr): | 16.10% |
|
|
Key People
| | • |
Chairman:
Max E. Link
| | • |
CEO, Secretary, Treasurer, and Director:
Leonard Bell
| | • |
VP Site Operations and Engineering:
Daniel N. Caron
|
|
|
